Contact Us

Overview

Technology

Nano-Pulse Stimulation (NPS™) is a proprietary technology that delivers nanosecond pulses of high-amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue.

These ultrafast electrical energy pulses have pulse durations from billionths up to a millionth of a second.

When applied to the targeted tissue, NPS energy pulses enter cells and alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum, without disrupting extracellular tissue. This leads to regulated cell death (RCD), a process exhibited by cells in the human body when they undergo stress and are unable to restore cellular homeostasis.

The CellFX System delivers pulses that directly affect the internal organelles of targeted cells but have no functional effect on non-cellular tissue, such as collagen (a proteinaceous tissue that forms the structural foundation of the skin). In short, it delivers a unique cell-focused effect to the internal structures of treated cells while preserving surrounding non-cellular tissue. This combination may lead to highly differentiated treatment applications.

The CellFX™ System is planned as a commercial product using NPS technology to create a non-toxic and non-thermal biophysical disruption of targeted cells, using tunable speed and amplitude of NPS pulses.

“Along with a team of qualified scientists, we have studied Pulse Biosciences’ core technology, the strength of leadership and management, patent portfolio, breadth of engineering and research talent, as well as our perceived long‐term sense of the robust potential of NPS technology in healthcare. We are impressed by what we have seen and with the experience, ability, and enthusiasm of the Pulse Biosciences team. We have previously worked closely with several members of the Pulse Biosciences management team, including Darrin Uecker, President, and CEO, and Dave Danitz and Edison Manuel, engineering and operations executives. Each of them were critical to our previous success at Computer Motion, Inc. (now part of Intuitive Surgical, Inc.) in launching computer-assisted robotics in the field of human surgery. We look forward to working with the Pulse Biosciences team on this important technology that we believe can impact healthcare in a meaningful and sustainable manner for the significant betterment of all,” Mr. Duggan and Dr. Zanganeh in a joint statement.